Expertise in
2
conditions

Cheng-lung Hsu

Taoyuan, TNQ, TW 
Expertise in
2
conditions
Taoyuan, TNQ, TW 

Overview

Cheng-lung Hsu practices practicing medicine in Taoyuan, Taiwan.

Hsu is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Nasopharyngeal Carcinoma, Mononucleosis, Throat Cancer, Laryngeal Cancer, and Orchiectomy.

They are actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 1 clinical trial.

Locations

Taoyuan, TNQ, Taiwan
Other Locations
Linkou, TPQ, Taiwan
Department Of Otolaryngology Head & Neck Surgery, 333423, Guishan, TPQ 33342, Taiwan
Taoyuan City, TNQ 33305, Taiwan
National Tsing Hua University Hsinchu 300044, Hsinchu, TNQ 30004, Taiwan
Department Of Otolaryngology Head And Neck Surgery, Keelung, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2

79 Total Publications

Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.
Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.
Journal: EJNMMI research
Published: April 28, 2026

Frequently Asked Questions about Cheng-lung Hsu

Is Cheng-lung Hsu a top-rated expert for Nasopharyngeal Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Cheng-lung Hsu is classified as an Advanced expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cheng-lung Hsu participate in research or clinical trials?

Yes. Cheng-lung Hsu has published 79 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Cheng-lung Hsu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsu's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile